TIDMGENI
RNS Number : 4139G
GENinCode PLC
19 July 2023
GENinCode Plc
("GENinCode" or the "Company")
Collaboration with US healthcare provider for CARDIO
inCode-Score (R) testing
MedStar to start clinical use of CARDIO inCode-Score(R)
polygenic testing to prevent cardiovascular disease
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics
company focused on the prevention of cardiovascular disease,
announces its collaboration with MedStar Health ("MedStar"), a
ten-hospital health system in the Washington, D.C. area, to use its
CARDIO inCode-Score(R) ("CIC-SCORE") test in primary care for the
risk assessment of coronary heart disease ("CHD"). Results of the
CIC-SCORE test will be combined with the standard American College
of Cardiology Atherosclerotic Cardiovascular Disease (ASCVD) Risk
Calculator to identify patients who could benefit from earlier
preventive treatment.
The C IC-SCORE test assesses an individual's polygenic (DNA)
risk of CHD which, together with their clinical risk, provides a
comprehensive risk assessment of CHD. It also addresses the
well-recognised need for improvement in CHD standard of care
practices.
As the largest healthcare provider in the Mid-Atlantic, MedStar
is an effective incubator for evaluating new clinical applications
and through this study, MedStar physicians will provide valuable
feedback on the clinical utility of C IC-SCORE in the primary care
setting. The clinical utility data generated will support coverage
determination and reimbursement for CIC-SCORE with the Centers for
Medicare and Medicaid Services (CMS). William Weintraub, MD ,
Director of Population Health Research at MedStar Health Research
Institute and Kristen Miller, PhD , Scientific Director for the
National Center for Human Factors in Healthcare at MedStar Health
Research Institute, are co-Primary Investigators and Christina
Schreiber, DO , a family medicine primary care provider with
MedStar, is the physician lead for the study.
The collaboration with MedStar represents the first major US
institution to begin clinically assessing CIC-SCORE, forming part
of the Early Access commercial programme now underway.
Clinicians have for many years recognised the importance of
prior CHD events (e.g. heart attack) within families of their
patients because genetic factors contribute to the development of
atherosclerosis and a patient's family history has become a
surrogate for their inherited genetic risk. In recent years, with
the advance of genomics, it has become possible to add genetic
profiling to conventional CHD risk factors. The combination of
genetics and conventional clinical risk factors will enhance the
predictive capability of a patient's risk resulting in a more
'personalised' approach to preventive care.
The CIC-SCORE test is a patent protected in-vitro diagnostic
polygenic test used to assess the risk of CHD. GENinCode procesess
the CIC-SCORE test at its laboratory in Irvine, California and
delivers online reports to physicians via its proprietary
cloud-based 'SITAB' platform.
Matthew Walls, CEO of GENinCode Plc said: "We are pleased to
announce our first major US clinical collaboration with MedStar,
which will focus on use of CIC-SCORE to identify patients at high
risk of heart disease, the largest cause of death in the US. We
look forward to working closely with the MedStar team to identify
patients at risk, inform personalised treatment and prevent
coronary heart disease."
William S. Weintraub Director of Population Health Research
MedStar Health Research Institute and Professor of Medicine at
Georgetown University commented : "We are delighted to collaborate
with GENinCode to implement CIC-SCORE for the prevention of
cardiovascular disease. This collaboration marks a major step in
primary care practice for the risk assessment of CHD and we welcome
this approach to help advance our clinical practice and reduce the
onset of cardiovascular disease."
For more information visit www.genincode.com
Enquiries:
GENinCode Plc www.genincode.com or via Walbrook PR
Matthew Walls, CEO
Stifel Nicolaus Europe Limited (Nomad and Joint Broker) Tel: +44 (0)20 7710 7600
Alex Price / Ben Maddison / Richard Short
Cenkos Securities Plc (Joint Broker) Tel: +44 (0)20 7397 8900
Giles Balleny / Max Gould
Dale Bellis / Michael Johnson (Sales)
Walbrook PR Limited Tel: 020 7933 8780 or genincode@walbrookpr.com
Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage
About GENinCode:
GENinCode Plc is a UK based company specialising in genetic risk
assessment of cardiovascular disease. Cardiovascular disease is the
leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through
GENinCode S.L.U, and in the United States through GENinCode U.S.
Inc.
GENinCode predictive technology provides patients and physicians
with globally leading preventative care and treatment strategies.
GENinCode CE marked invitro-diagnostic molecular tests combine
clinical-genetic algorithms and bioinformatics to provide advanced
patient risk assessment to predict disease onset.
About MedStar Health:
MedStar Health combines the best aspects of academic medicine,
research, and innovation with a complete spectrum of clinical
services to advance patient care. As the largest healthcare
provider in Maryland and the Washington, D.C., region, MedStar
Health's more than 300 care locations include 10 hospitals, 33
urgent care clinics, ambulatory care centers, and primary and
specialty care providers. MedStar Health is also home to the
MedStar Health Research Institute and a comprehensive scope of
health-related organizations all recognized regionally and
nationally for excellence. MedStar Health has one of the largest
graduate medical education programs in the country, training 1,150
medical residents annually, and is the medical education and
clinical partner of Georgetown University. MedStar Health is a $6.7
billion, not-for-profit, regional healthcare system based in
Columbia, Maryland, and one of the largest employers in the region.
MedStar Health's team of more than 31,000 includes physicians,
nurses, and many other clinical and non-clinical associates who
together support MedStar Health's patient-first philosophy that
combines care, compassion, and clinical excellence with an emphasis
on customer service . Visit MedStarResearch.org for more
information.
About Cardiovascular Disease (CVD):
GENinCode specializes in polygenic risk assessment of CVD, the
leading cause of death and disability worldwide. CVD is a broad
disease classification which encompasses coronary heart disease
("CHD") (causing angina, heart attack and heart failure),
cerebrovascular disease (causing stroke, and some dementia),
peripheral vascular disease (causing limb ischaemia, and some
chronic kidney disease) and venous thromboembolism. CHD is the most
common type of heart disease in the US and is often referred to as
coronary artery disease or ischemic heart disease. For some people,
the first sign of CHD is a heart attack. CHD is caused by plaque
build up in the walls of the arteries that supply blood to the
heart (coronary arteries) and other parts of the body.
CVD accounts for an estimated 17.9 million deaths globally each
year and accounts for 1 in every 4 deaths in the United States. By
2030 the global cost of CVD is set to rise from approximately
US$863 billion in 2010 to US$1,044 billion and is both a major
health issue and global economic burden. More than four out of five
CVD deaths are due to heart attacks and strokes, and one third of
these deaths occur prematurely in people under 70 years of age.
The current standard of care for assessing cardiovascular risk
is based on traditional clinical risk factors such as age, sex,
smoking, blood pressure and cholesterol levels from which
individuals are categorized as being at low, borderline,
intermediate or high risk of a CHD event. This categorization is
imperfect as CHD events frequently occur in those thought to be at
low or intermediate risk. The size of the populations classified at
low through to intermediate risk are much larger than those at high
risk so whilst the relative risk of a CHD event may be small, the
absolute number of CHD events in low and moderate risk populations
is much greater than the number of events in higher risk
categories.
The most important behavioural risk factors of heart disease and
stroke are unhealthy diet, physical inactivity, tobacco use and
harmful use of alcohol. The effects of behavioural risk factors may
show up in individuals as raised blood pressure, raised blood
glucose, raised blood lipids, overweight and obesity. These
"behavioural risks factors" can be measured in primary care
facilities and indicate an increased risk of heart attack, stroke,
heart failure and other complications. Genetic risk assessment
helps to identify individuals in low or moderate risk populations
who are at higher risk of a CHD event than their traditional
clinical risk categorisation would suggest. This allows earlier
in-life preventative measures to be put in place to lower their
future risk.
Identifying those at highest risk of CVDs and ensuring they
receive appropriate treatment can prevent premature death. Access
to noncommunicable disease medicines and basic health technologies
in all primary health care facilities is essential to ensure that
those in need receive treatment and counselling.
Cardiovascular disease causes a quarter of all deaths in the US
and is the largest cause of premature mortality in deprived areas
and is typically the single biggest area of national health care
strategy where lives can be saved. CVD is largely preventable,
through lifestyle changes, education and a combination of public
health strategy for treatment and action on smoking and tobacco
addiction, obesity, tackling alcohol misuse and food
reformulation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLFEVDTITLIV
(END) Dow Jones Newswires
July 19, 2023 02:00 ET (06:00 GMT)
Genincode (LSE:GENI)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Genincode (LSE:GENI)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
